<DOC>
	<DOCNO>NCT01404715</DOCNO>
	<brief_summary>This study address follow question : Does imatinib influence pharmacokinetics metformin healthy volunteer ? Recent study Giacomini laboratory indicate imatinib may block metformin elimination kidney inhibit organic cation transporter efflux metformin . 1 . The investigator hypothesize addition imatinib metformin therapy reduce renal clearance ( CLR ) metformin lead increase plasma concentration risk toxicity 2 . Knowledge pharmacokinetic interaction profile metformin organic cation transporter inhibitor , imatinib , important help develop safe effective drug therapy reduce side effect .</brief_summary>
	<brief_title>Drug-drug Interaction Study With Metformin Imatinib</brief_title>
	<detailed_description>Screening Procedures : Prior enrollment , subject ask come Clinical Translational Science ( CTSI ) Clinical Research Centre ( CRC ) San Francisco General Hospital ( SFGH ) . The study protocol procedure explain detail , question answer , subject provide consent form sign . The screening visit must conduct within 14 day first inpatient visit i.e . first metformin alone metformin imatinib dose day . Only subject consent participate study screen procedure commence . All subject recruit study already consent pharmacogenomics ethnically diverse population ( SOPHIE ) study , previously establish cohort healthy people live San Francisco . A review subject 's medical history health questionnaire conduct , research staff , re-assess health status confirm eligibility . Changes medical drug use history note study . During screen visit , vital sign well blood urine sample take subject laboratory analysis . A single blood sample ( 10 mL ) take venipuncture measure complete blood count ( CBC ) , electrolytes , blood urea nitrogen ( BUN ) , creatinine , liver function test ( LFTs ) screen anemia renal hepatic insufficiency ( see Inclusion/Exclusion Criteria ) . After screen visit , equal number subject randomize , random number generator excel , one two study arm ; metformin alone follow co-administration metformin imatinib . Procedures During Main Study : Randomized Study Visit Arm 1 : Metformin alone Subjects report CRC approximately 7:30 AM , overnight fast least 10 hour ( since approximately 10:00 PM ) . Vital sign brief history take upon arrival . If inclusion/exclusion criterion meet , one intravenous ( IV ) catheter insert forearm vein facilitate blood sample . An initial blood sample 10 mL drawn IV line determination plasma metformin , creatinine , imatinib concentration prior administration metformin ( i.e . baseline measurement ) . Next subject receive oral dose 1000 mg metformin 8 oz water follow oral dose 850mg . Blood sample ( 5 mL ) drawn 0.5 , 1 , 1.5 , 2 , 2.5 , 3 , 3.5 , 4 , 6 , 8 , 10 , 12 , 24 hour post-dose determination plasma metformin imatinib concentration . An additional 5 mL blood draw 6-hour 12-hour time point measurement serum creatinine allow calculation creatinine clearance ( CLcr ) . Blood sample obtain finger prick take 0 , 0.5 , 1 , 1.5 , 2 , 2.5 , 3 , 3.5 4 hour ingestion metformin ( total 0.1 mL ) measure blood glucose level . Additional biomarkers metformin/imatinib response toxicity , plasma insulin , glucose AMPK activation , may also determine blood sample collect . Subjects remain CRC receive standardize meal start 4 hour post metformin dose . Subjects discharge allow go home follow morning collection 24 hour blood urine sample approximately 8 AM . All blood sample centrifuge , plasma separate immediately store -80oC analysis . Urine collection : Subjects ask void bladder prior metformin administration ( baseline urine sample ) drink 8 oz water every 4 hour maintain urine flow pH . Aliquots urine collect following time frame : 0-2 , 2-4 , 4-8 , 8-12 , 12-24 hour post metformin dosing . Additionally , aliquots collection take 0-12 0-24 hour pool analysis creatinine . Subjects advise collect urine produce inpatient visit . The volume pH urine collection record aliquot ( 20 mL ) collection period store -80Â°C determination urinary metformin creatinine concentration . Randomized Study Visit Day 2 : Co-administration metformin imatinib Subjects present CRC overnight fast previously describe . After collection baseline blood urine sample , subject receive oral dose 600 mg imatinib 1000 mg metformin 8 oz water follow oral dose 850mg . The study procedures describe `` Randomized Study Visit Day 1 '' `` Urine collection '' repeat . Study Restrictions : Concomitant Medications : The study require healthy participant refrain take medication ( except daily vitamins oral contraceptive ) duration study , particular medication ( ) interfere pharmacokinetics metformin imatinib ( See Exclusion criterion 13.7 ) . Other Study Restrictions : Subjects require use adequate contraceptive mean avoid pregnancy throughout study . Subjects must remain within CRC throughout two 24 hour inpatient visit unless accompany CRC staff member . Subjects refrain smoke ingest caffeine , alcohol , orange grapefruit juice contain product night inpatient study day study complete , approximately 24 hour dose . Clinical Laboratory Determinations : Measurement metformin , creatinine , imatinib CGP74588 plasma urine preform High Performance Liquid Chromatography ( HPLC ) tandem mass spectrometry ( MS/MS ) use assay previously describe validate . Hematology , Blood Chemistry Urinalysis : The follow standard biochemistry , blood chemistry urinalysis perform screening visit : 1 . Hematology , ( Complete Blood Count differential , CDP ) : WBC differential , red blood cell ( RBC ) , RBC index ( HGB , HCT , MCV , MCH , MCHC ) platelet count . 2 . Blood chemistry ( Metabolic Comprehensive Panel , METC ) : sodium , potassium , chloride , carbon dioxide , creatinine , blood urea nitrogen , glucose , calcium , bilirubin ( total ) , phosphate ( total ) , AST , ALT , albumin alkaline phosphatase 3 . Urinalysis : urine protein ( dipstick ) blood ( dipstick ) .</detailed_description>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Age 1845 year Male female If female , use appropriate contraception Healthy judge medical examination , medical history normal biochemical hematological measure Normal urinalysis renal function Understand nature purpose study provide inform consent Pregnant lactate woman ( female subject urine pregnancy test screen visit ) Abnormal bone marrow function ( leukocyte , neutrophil , platelet count outside normal range ) History hypersensitivity allergic reaction metformin imatinib Risk congestive heart failure require pharmacologic treatment ( medical history ) History renal hepatic dysfunction ( e.g. , CLcr &lt; 60mL/min , ALT &gt; 80U/L , AST &gt; 60 U/L ) Anemic ( hemoglobin &lt; 12 g/dL ) Use medication ( include counter product , herbal product , mineral supplement ) exception daily vitamin oral contraceptive . In particular use medication know interfere pharmacokinetics metformin imatinib cimetidine , cetirizine , ketoconazole , procainamide , St. John 's Wort , testosterone prohibit . Subjects undergo radiologic study involve intravascular administration iodinate contrast material , use product may result acute alteration renal function Laboratory parameter 2 standard deviation laboratory mean Subject carry MATE1 gene variant predict effect MATE1 protein expression</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Drug drug interaction</keyword>
</DOC>